Connect
MJA
MJA

Measuring performance and outcomes of acute coronary syndromes management in Australia

Derek Chew, David Brieger, Carolyn M Astley and Andrew Georgiou
Med J Aust 2012; 197 (3): 140-142. || doi: 10.5694/mja11.11259
Published online: 6 August 2012

A national registry for acute coronary syndromes will improve patient care and clinical results

Acute coronary syndromes (ACS) represent a substantial burden of morbidity and mortality within Australia.1 Modern treatment of these syndromes requires efficient risk stratification, timely angiography and revascularisation, and use of proven secondary prevention therapies.2-4 With a robust evidence base, it is a reasonable societal expectation that care be applied as completely as possible, to optimise recovery and secondary prevention. Clinical performance measures for ACS care have a central role in facilitating the translation of the evidence base into improved clinical outcomes.

  • Derek Chew1,2
  • David Brieger3,4
  • Carolyn M Astley5
  • Andrew Georgiou6

  • 1 School of Medicine, Flinders University, Adelaide, SA.
  • 2 Southern Adelaide Local Health Network, Adelaide, SA.
  • 3 Concord Hospital, Sydney, NSW.
  • 4 Faculty of Medicine, University of Sydney, Sydney, NSW.
  • 5 Flinders Medical Centre, Adelaide, SA.
  • 6 Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, University of New South Wales, Sydney, NSW.


Acknowledgements: 

We thank Colleen Bichel, Neville Board, Carrie Toohey, Karen Uhlmann and Jinty Wilson for contributions to and review of our article.

Competing interests:

Derek Chew has served on advisory boards for AstraZeneca and Eli Lilly and has received consultancy fees for Flinders University from Abbott Vascular and payment for lectures from AstraZeneca. David Brieger has served on advisory boards for and has received payment for lectures from AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Sanofi, and has received research grants to the University of Sydney from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi and Merck.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.